OPPEL RAYMOND
Known title: DirectorCIK: 0001187503
Associated companies
Transaction History
| MTH | ▲ Buy | Grant | 1,500 | $0 | 2/22/2024 | View on chart |
| MTH | ▼ Sell | Open Market | 5,000 | $551K | 3/3/2023 | View on chart |
| MTH | ▼ Sell | Open Market | 5,000 | $533K | 2/22/2023 | View on chart |
| MTH | ▲ Buy | Grant | 2,100 | $0 | 2/16/2023 | View on chart |
| MTH | ▲ Buy | Grant | 2,500 | $0 | 2/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Melius Research initiates Meritage Homes coverage with Sell rating
Melius Research began tracking Meritage Homes with a Sell rating and a $59 price target. This new negative view adds to recent pressure on the stock, which is currently trading near its 52-week low. The move follows a broader trend of weakness in the homebuilder sector, as seen in recent declines for peers like Lennar.
Melius Research initiates Meritage Homes coverage with Sell rating. Melius Research began tracking Meritage Homes with a Sell rating and a $59 price target. This new negative view adds to recent pressure on the stock, which is currently trading near its 52-week low. The move follows a broader trend of weakness in the homebuilder sector, as seen in recent declines for peers like Lennar.